Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new articles that discuss program directors’ response to the use of generative AI for personal statements, the good news for neurology based on the 2024 Match Day, and the AHS statement on CGRP-targeting therapies as a game changer for migraine treatment.

Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.

Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.

Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the impact of SARS-CoV2 on dopamine neurons, a European Medicines Agency warning about valproate risks for men, and neurologists on the pros and cons of working locum tenens.

Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the use of AI in EMS systems for stroke detection, the association between human growth hormone and iatrogenic Alzheimer’s, and seizure dogs for refractory epilepsy.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a new study showing retinal vascular perfusion as a migraine biomarker, clinical and pathophysiological correlates of posterior cortical atrophy, and advances in gene therapies for neuromuscular disorders.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing the cerebral amyloid angiopathy as a risk factor for nontraumatic subdural hemorrhage, AI beats humans in neurology-like boards, and the impact of popular weight loss drugs on neurologic conditions.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing the rising incidence of Creutzfeldt-Jakob disease, an effective therapy for prodromal migaine, and neuroinflammation in military personnel exposed to blast injury.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies on the impact of deep brain stimulation on cognition in severe traumatic brain injury and how adaptive functioning is impacted in children exposed to antiseizure drugs in utero, and the editorial board’s picks for the best advances of 2023.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing double the suicide risk among Parkinson’s patients; underrepresentation of non-White people in Alzheimer’s trial related to biomarker eligibility; early immune systems changes may play early role in ALS and Parkinson's.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing serotonin depletion associated with long COVID; implantable cardiac monitors detect Afib 3 years post-stroke; and what Medicare’s decision to cover PET amyloid scans means for neurologists.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies on a promising potassium channel opener for refractory epilepsy; the impact of adverse childhood events in headache disorders; and excessive engulfment by microglia/astroctyes in dementia.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on the risk of spontaneous intracerebral hemorrhages after blood transfusions; the burden of long distance travel to see neurologists; and two promising biomarkers for early diagnosis of Parkinson’s disease.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on blood pressure targets for stroke after endovascular therapy, changing policies on CME, and a direct-to-consumer blood test for Alzheimer’s disease.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on football and the risk for Parkinson’s disease, the potential of deep brain stimulation for recovery from stroke, and neuroprostheses for patients with anarthria.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses the Medicare’s proposed coverage of carotid stenting in asymptomatic patients,neuro-oncologists’ perspectives on a federal initiative to target persistent poverty in vulnerable patients, and the technological promise of a new optical EMG for neuromuscular disorders.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses research that assesses the safety of endovascular treatment post-stroke for people with intracranial tumors, the AANEM guideline on IVIG use for neuromuscular disorders, and the latest data on donanemab.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses studies that associate poor oral health and risk for cognitive decline and how to manage first-ever sleep seizures that recur as well as the growth of concierge neurology.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses studies that identify gene variants associated with MS severity/progression, an AI program that read EEGs accurately, and butylphthalide as a promising neuroprotective agent for ischemic stroke.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a novel therapeutic approach that induced antigen tolerance in an MS mouse model, the association between epileptiform activity and ICU outcomes, and an agent, vorasidenib, that slows low-grade gliomas.

In this week’s podcast, Neurology Today’s editor-in-chief discusses the association between gout and neurodegenerative diseases, tenecrteplase vs.warfarin for acute stroke, expedited cognitive decline after a heart attack.

In this week’s podcast, Neurology Today’s editor-in-chief discusses the FDA approval of an antipsychotic for agitation in dementia, elevated risk for Parkinson’s in Camp Lejeune Marines exposed to contaminated water, a gene variant delays the onset of symptoms in man with autosomal dominant Alzheimer’s. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

In this week’s podcast, Neurology Today’s editor-in-chief discusses a study on the safety of omnabotuliumtoxinA on pregnant women with migraine, the impact of the Adderall shortage on patients with ADHD and narcolepsy, and the state of AI for epilepsy. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

In this week’s podcast, Neurology Today’s editor-in-chief discusses a new study reporting a gene assay detected Parkinson’s before symptoms onset, life stressors greatly impact women with epilepsy during pregnancy; the role of inflammation in new-onset refractory status epilepticus.  This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.